%0 Journal Article
%T Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
%J -
%D 2019
%R https://doi.org/10.1016/j.ccell.2019.04.006
%X £¿ Ripretinib broadly inhibits primary and drug-resistant KIT/PDGFRA mutants £¿ KIT/PDGFRA inhibitor of all known activation loop mutations £¿ In drug-resistant cancers, ripretinib blocks kinase signaling and tumor growth £¿ Circulating tumor DNA data confirm broad inhibition of mutant KIT in GIST patient
%U https://www.cell.com/cancer-cell/fulltext/S1535-6108(19)30201-6